^
    Back
    Association details:
    Biomarker:KRAS Q61H
    Cancer:Colorectal Cancer
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Vectibix (panitumumab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancer Discov
    Title:

    Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

    Excerpt:
    Biopsy of a different segment 5 liver metastasis that progressed despite panitumumab and trametinib revealed that this lesion harbored the same KRAS p.Q61H mutation…
    DOI:
    10.1158/2159-8290.CD-15-1283
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Cancer Discov
    Title:

    Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer

    Excerpt:
    Biopsy of a patient's progressing liver metastasis following prolonged response to cetuximab revealed a MEK1(K57T) mutation as a novel mechanism of acquired resistance. This lesion regressed upon treatment with panitumumab and the MEK inhibitor trametinib. In circulating tumor DNA (ctDNA), mutant MEK1 levels declined with treatment, but a previously unrecognized KRAS(Q61H) mutation was also identified that increased despite therapy.
    DOI:
    10.1158/2159-8290.CD-15-1283